People: CSL Ltd (CSL.AX)

CSL.AX on Australia Stock Exchange

72.94AUD
19 Sep 2014
Price Change (% chg)

$0.33 (+0.45%)
Prev Close
$72.61
Open
$73.05
Day's High
$73.26
Day's Low
$72.93
Volume
1,202,243
Avg. Vol
1,210,403
52-wk High
$75.13
52-wk Low
$63.77

Search Stocks

Summary

Name Age Since Current Position

John Shine

67 2011 Independent Non-Executive Chairman of the Board

Paul Perreault

56 2013 Chief Executive Officer, Managing Director, Executive Director

Gordon Naylor

50 2010 Chief Financial Officer

Greg Boss

52 Group General Counsel, Executive Vice President - Legal

Karen Etchberger

55 2013 Executive Vice President - Quality and Business Services

Ingolf Sieper

58 2011 Executive Vice President - Commercial Operations

Mary Sontrop

56 2010 Executive Vice President - Manufacturing and Planning

Jill Lever

57 2009 Senior Vice President - Human Resources

Andrew Cuthbertson

58 Chief Scientific Officer

Mark Dehring

Director of Investor Relations, IR Contact Officer

Edward Bailey

47 Company Secretary, Australian General Counsel

John Akehurst

2004 Independent Non-Executive Director

David Anstice

65 2008 Independent Non-Executive Director

Bruce Brook

58 2011 Independent Non-Executive Director

Marie McDonald

57 2013 Non-Executive Independent Director

Christine O'Reilly

52 2011 Independent Non-Executive Director

Maurice Renshaw

66 2004 Independent Non-Executive Director

Biographies

Name Description

John Shine

Prof. John Shine, Ph.D, has been Independent Non-Executive Chairman of the Board of CSL Limited since October 19, 2011. He is Professor of Molecular Biology and Professor of Medicine at the University of NSW, and a Director of many scientific research and medical bodies throughout Australia. Professor Shine is President of the Museum of Applied Arts and Science (Powerhouse Museum and Sydney Observatory) and was formerly Executive Director of the Garvan Institute of Medical Research. He was also formerly Chairman of the National Health and Medical Research Council and a Member of the Prime Minister’s Science, Engineering and Innovation Council. In November 2010, he was awarded the 2010 Prime Minister’s Prize for Science. Professor Shine is a member of the Innovation and Development Committee.

Paul Perreault

Mr. Paul Perreault has been Chief Executive Officer, Managing Director and Executive Director of CSL Ltd since July 1, 2013. Paul Perreault was appointed to the CSL Board in February 2013 and is the Chief Executive Officer and Managing Director. Paul joined a CSL predecessor company in 1997 and has held senior roles in sales, marketing and operations with his most recent prior position being President, CSL Behring. He has also worked in senior leadership roles with Wyeth, Centeon, Aventis Bioservices and Aventis Behring. Paul was previously Chairman of the Global Board for the Plasma Protein Therapuetics Association. He has had more than 30 years experience in the global healthcare industry. Mr Perreault is a member of the Innovation and Development Committee.

Gordon Naylor

Mr. Gordon Naylor has been Chief Financial Officer of CSL Ltd since January 1, 2010. He joined CSL in 1987 and has held many operational and corporate roles in different parts of the CSL Group. Prior to his current role, Gordon was based in the US and responsible for CSL Behring’s global supply chain, the supply of plasma for CSL Behring and CSL’s global information systems.

Greg Boss

Mr. Greg Boss is Group General Counsel, Executive Vice President - Legal of CSL Ltd. Greg was appointed Group General Counsel in 2009 and is responsible for worldwide legal operations for all CSL Group companies. He joined CSL in 2001, serving as General Counsel for CSL Behring, a position he continues to hold. In addition, Greg is also responsible for risk management for the Group. Prior to joining CSL, Greg was Vice President and Senior Counsel for CB Richard Ellis International.

Karen Etchberger

Ms. Karen Etchberger is Executive Vice President - Quality and Business Services of CSL Ltd. Karen was appointed as Executive Vice President, Quality and Business Services in April 2013 with responsibility for quality, information, technology, logistics, sourcing and enterprise project management. Prior to that she was Executive Vice President, Plasma, Supply Chain and Information Technology. Karen joined CSL as a Product Manager at JRH Biosciences in 2001 and progressed through a number of positions in technical services, quality management and research and development. Prior to joining CSL, she was Director of Developmental Research at Endotech Corporation.

Ingolf Sieper

Dr. Ingolf Sieper is Executive Vice President - Commercial Operations of CSL Ltd since 2011. He is responsible for all sales and marketing activities globally for CSL Behring. Ingolf joined a CSL predecessor company in 1986 and has a strong background in marketing and management in the coagulation, diagnostic and plasma protein divisions. Among the roles in which he has served, Ingolf was Vice President and General Manager, Commercial Operations, Central Europe, with responsibility for CSL Behring’s commercial activities in Germany, Switzerland, Austria and Slovenia.

Mary Sontrop

Ms. Mary Sontrop is Executive Vice President - Manufacturing and Planning of CSL Ltd. Mary was appointed as Executive Vice President, Manufacturing and Planning in 2010. She joined CSL as a Production Manager in 1988 and has held a broad range of positions in manufacturing, quality management and general management located in Australia, Switzerland and Germany. Prior to her current position, Mary was General Manager of CSL Biotherapies for Australia and New Zealand.

Jill Lever

Ms. Jill Lever has been Senior Vice President - Human Resources of CSL Ltd since June 1, 2009. Jill joined CSL Limited as Senior Vice President, Human Resources in 2009. She heads the global Human Resources function and works with the Managing Director and Board on strategic matters relating to talent, succession, organisation culture and executive remuneration. Originally from the UK, Jill held a number of Human Resources roles with the Royal Dutch Shell Group in Europe, the Middle East, South America and Asia Pacific before working in the finance and mining sectors in Melbourne.

Andrew Cuthbertson

Dr. Andrew Cuthbertson is Chief Scientific Officer of CSL Ltd. He is responsible for CSL’s Research and Development strategy and the implementation of that strategy. He joined CSL in March 1997 as Director of Research. He trained in medicine and science at the university of Melbourne, the Walter and Eliza Hall Institute, the Howard Florey Institute and the National Institutes of Health in the United States. He was then a Senior Scientist at Genentech, Inc. in San Francisco.

Mark Dehring

Edward Bailey

Mr. Edward H. Bailey B.Com/LLB, FCIS, is Company Secretary and Australian General Counsel of CSL Limited. Mr. Bailey joined CSL Limited in 2000 and had occupied the role of Assistant Company Secretary from 2001. Before joining CSL Limited, Mr. Bailey was a Senior Associate with Arthur Robinson & Hedderwicks.

John Akehurst

Mr. John H. Akehurst MA (Oxon), FIMechE, has been Independent Non-Executive Director of CSL Limited since April 1, 2004. He had 30 years’ executive experience in the international hydrocarbon industry, including seven years as Managing Director and CEO of Woodside Petroleum Ltd. Mr Akehurst is a member of the Board of the Reserve Bank of Australia and is a Director of Origin Energy Limited, and Transform Exploration Pty Ltd. He was formerly Chairman of Alinta Limited and of Coogee Resources Limited and is a former Director of Oil Search Limited. Mr Akehurst is Chairman of the National Centre for Asbestos Related Diseases and the Fortitude Foundation. Mr Akehurst is Chairman of the Human Resources and Remuneration Committee

David Anstice

Mr. David W. Anstice BEc, has been Independent Non-Executive Director of CSL Limited since September 2, 2008. He was a long-time member of the Board of Directors and Executive Committee of the US Biotechnology Industry Organisation, and has over 40 years’ experience in the global pharmaceutical industry. Until August 2008, Mr Anstice was for many years a senior executive of Merck & Co. Inc. serving at various times as President of Merck Human Health for US/Canada/ Latin America, Europe, Japan and Asia, and upon retirement was an Executive Vice President. He is a Director of Alkermes Plc, Dublin, Ireland, and a Director of the United States Studies Centre at the University of Sydney. Mr Anstice is a member of the Human Resources and Remuneration Committee and the Innovation and Development Committee.

Bruce Brook

Mr. Bruce Robert Brook has been Independent Non-Executive Director of CSL Limited since August 17, 2011. He is currently Chairman of Programmed Maintenance Services Limited and a Director of Boart Longyear Limited and Newmont Mining Corporation. Mr Brook has previously been Chairman of Energy Developments Limited and a Director of Lihir Gold Limited and Consolidated Minerals Limited. During his executive career he was Chief Financial Officer of WMC Resources Limited and prior to that the Deputy Chief Financial Officer of the ANZ Banking Group. Mr Brook is a member of the Audit and Risk Management Committee.

Marie McDonald

Ms. Marie McDonald has been Non-Executive Independent Director of CSL Ltd since August 14, 2013. For many years she has practised in company and commercial law and is a partner of Ashurst (formerly Blake Dawson). Ms McDonald is currently Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia, having previously been a Deputy Chair, and was also a member of the Australian Takeovers Panel from 2001 to 2010.

Christine O'Reilly

Ms. Christine E. O'Reilly has been Independent Non-Executive Director of CSL Limited since February 16, 2011. She is a Director of the Transurban Group, Energy Australia, Baker IDI and Care Australia. During her executive career, she was Co-Head of Unlisted Infrastructure Investments at Colonial First State Global Asset Management and prior to that was the Chief Executive Officer of the GasNet Australia Group. Ms O’Reilly is a member of the Audit and Risk Management Committee and the Human Resources and Remuneration Committee.

Maurice Renshaw

Mr. Maurice A. Renshaw has been Independent Non-Executive Director of CSL Limited since July 20, 2004. Formerly, he was Vice President of Pfizer Inc, USA, Executive Vice President, Pfizer Global Consumer Group and President of Pfizer’s Global Consumer Healthcare Division. Prior to his positions in Pfizer, Mr Renshaw was Vice President of Warner Lambert Co. and President of Parke-Davis USA. He has had more than 35 years’ experience in the international pharmaceutical industry. Mr Renshaw is Chairman of the Innovation and Development Committee.

Basic Compensation

Name Fiscal Year Total

John Shine

589,618

Paul Perreault

3,036,160

Gordon Naylor

2,374,840

Greg Boss

1,488,180

Karen Etchberger

1,190,160

Ingolf Sieper

1,483,290

Mary Sontrop

2,081,460

Jill Lever

1,057,220

Andrew Cuthbertson

1,954,660

Mark Dehring

--

Edward Bailey

963,304

John Akehurst

--

David Anstice

--

Bruce Brook

--

Marie McDonald

--

Christine O'Reilly

--

Maurice Renshaw

--
As Of 29 Jun 2013
Search Stocks